Northeast Financial Consultants Inc acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 4,000 shares of the company’s stock, valued at approximately $323,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of OMCL. Parallel Advisors LLC purchased a new position in shares of Omnicell during the 1st quarter valued at $28,000. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Omnicell by 451.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock valued at $38,000 after acquiring an additional 506 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Omnicell by 125.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after acquiring an additional 300 shares in the last quarter. IFP Advisors Inc grew its holdings in shares of Omnicell by 109.3% during the 4th quarter. IFP Advisors Inc now owns 741 shares of the company’s stock valued at $45,000 after acquiring an additional 387 shares in the last quarter. Finally, Manchester Capital Management LLC purchased a new position in shares of Omnicell during the 1st quarter valued at $49,000. Hedge funds and other institutional investors own 97.32% of the company’s stock.
OMCL has been the topic of several research analyst reports. Benchmark boosted their price target on shares of Omnicell from $82.00 to $90.00 and gave the company a “buy” rating in a report on Friday, April 26th. Craig Hallum cut shares of Omnicell from a “buy” rating to a “hold” rating and set a $84.00 price target on the stock. in a report on Friday, April 26th. ValuEngine upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Dougherty & Co boosted their price target on shares of Omnicell from $78.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, March 7th. Finally, BidaskClub upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $79.89.
Shares of NASDAQ:OMCL opened at $82.79 on Friday. The firm has a market capitalization of $3.44 billion, a P/E ratio of 54.11, a price-to-earnings-growth ratio of 2.71 and a beta of 1.15. Omnicell, Inc. has a 1 year low of $49.45 and a 1 year high of $86.87. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.96 and a quick ratio of 1.47.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, April 25th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.38. The firm had revenue of $202.50 million during the quarter, compared to analysts’ expectations of $199.72 million. Omnicell had a net margin of 4.74% and a return on equity of 11.10%. Omnicell’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 earnings per share. As a group, equities analysts anticipate that Omnicell, Inc. will post 2.06 EPS for the current year.
In other Omnicell news, insider Joseph Brian Spears sold 6,450 shares of the business’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $79.62, for a total transaction of $513,549.00. Following the completion of the transaction, the insider now owns 19,112 shares of the company’s stock, valued at approximately $1,521,697.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Nhat H. Ngo sold 1,823 shares of the business’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $82.33, for a total transaction of $150,087.59. Following the transaction, the executive vice president now directly owns 37,569 shares of the company’s stock, valued at approximately $3,093,055.77. The disclosure for this sale can be found here. Insiders sold 131,224 shares of company stock valued at $9,469,511 over the last quarter. 2.77% of the stock is currently owned by corporate insiders.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: Equity Income
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.